Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial

[1]  J. Lutz,et al.  Haemostasis in chronic kidney disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Practical considerations for the dosing and adjustment of continuous renal replacement therapy in the intensive care unit. , 2013, Journal of critical care.

[3]  Jeffrey B Hall,et al.  PF4/Heparin Antibody Testing and Treatment of Heparin-Induced Thrombocytopenia in the Intensive Care Unit , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[4]  Sushrut S Waikar,et al.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  H. Watson,et al.  Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition , 2012, British journal of haematology.

[6]  Adam Cuker,et al.  Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. , 2012, Blood.

[7]  T. Warkentin.  Heparin-induced thrombocytopenia in the ICU: a transatlantic perspective. , 2012, Chest.

[8]  V. Louvain-Quintard,et al.  Clinical and biologic features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. , 2012, Chest.

[9]  R. Becker,et al.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician , 2012, Journal of Thrombosis and Thrombolysis.

[10]  C. Murphy,et al.  Bleeding risk factors associated with argatroban therapy in the critically ill , 2012, Journal of Thrombosis and Thrombolysis.

[11]  A. Dans,et al.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[12]  Gordon H Guyatt,et al.  Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2012 .

[13]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[14]  B. Ivandic,et al.  Monitoring of the Anticoagulants Argatroban and Lepirudin , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[15]  A. Lincoff,et al.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[16]  J. Peters,et al.  Argatroban in extracorporeal membrane oxygenation. , 2007, Artificial organs.

[17]  J. Peters,et al.  Argatroban Anticoagulation in Critically III Patients , 2007, The Annals of pharmacotherapy.

[18]  D. Cook,et al.  Bleeding during critical illness: a prospective cohort study using a new measurement tool. , 2007, Clinical and investigative medicine. Medecine clinique et experimentale.

[19]  T. Warkentin,et al.  Testing for heparin-induced thrombocytopenia antibodies. , 2006, Transfusion medicine reviews.

[20]  A. Greinacher,et al.  Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia , 2006, European journal of haematology.

[21]  C. Sigouin,et al.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  M. Franchini.  Heparin-induced thrombocytopenia: an update , 2005, Thrombosis journal.

[23]  R. White,et al.  Argatroban for Heparin-Induced Thrombocytopenia in Hepato-Renal Failure and CVVHD , 2003, The Annals of pharmacotherapy.

[24]  J. Walenga.  An Overview of the Direct Thrombin Inhibitor Argatroban , 2003, Pathophysiology of Haemostasis and Thrombosis.

[25]  J. Bartholomew,et al.  Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia , 2001, Circulation.

[26]  L. Goldman,et al.  The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. , 1989, Journal of clinical epidemiology.